← Library
Tesamorelin
FDA ApprovedSince 2010
Also known as Egrifta, Egrifta SV
Function
Primary
HIV-associated lipodystrophy · Visceral fat reduction
Secondary
Cognitive aging (investigational)
Mechanism
Stabilized GHRH analog — stimulates GH release, reduces visceral adiposity; Phase II data for cognitive decline in MCI/Alzheimer's.
Evidence
Clinical RCT (Phase III)
Research
Phase III Theratechnologies; Phase II cognition data
Dosing
Range
2 mg/day
Frequency
Once daily
Route
Subcutaneous
Cycling
Continuous; periodic IGF-1 monitoring.
Benefits
- ·Visceral fat reduction
- ·Improved lipid profile
- ·Possible cognitive benefits in MCI
Risks
- ·IGF-1 elevation (monitoring required)
- ·Fluid retention
- ·Arthralgia
- ·Hyperglycemia
Contraindications
- ·Active malignancy
- ·Hypopituitarism with GH deficiency only
- ·Pregnancy
Regulatory
FDA-Approved (HIV lipodystrophy); off-label longevity use
Functional Groups
Cited Works
- Falutz J et al. Effects of tesamorelin on visceral fat in HIV-associated lipodystrophy. N Engl J Med. 2007;357:2359.source